Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the humoral and cell-mediated immune responses in HIV-infected adults who had previously received rabies booster vaccination more than a year before

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination

NCT01286493

HIV Rabies

COMPLETED NA

Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults

NCT02547727

Rabies

UNKNOWN NA

Diagnostic Immunization With Rabies Vaccine in Patients With PID

NCT02490956

Primary Immunodeficiency

UNKNOWN PHASE4

Study of Immune Responses Induced by a HIV Vaccine

NCT01933685

HIV Infections

UNKNOWN PHASE2

HIV Vaccine Trial in Thai Adults

NCT00223080

HIV Infection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Previous study has shown the higher immunogenicity response among HIV-infected adults who received a single visit 4-site intradermal rabies booster vaccination than those who received the conventional intramuscular regimen. The investigators follow the persistence of these effects. Also, the regulatory T cell levels were examined after the rabies booster vaccination .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rabies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

The volunteers who participated in the previous clinical trials were invited to join this study. Of which, there were 2 groups, one received a single visit 4-site intradermal rabies booster vaccination. The another received a conventional intramuscular rabies booster vaccination on day 0 and 3.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

single visit 4-site ID vaccination

Blood would be drawn from those who received a single visit 4-site ID rabies booster vaccination in the previous trial.

Group Type EXPERIMENTAL

Blood drawn after rabies booster vaccination

Intervention Type PROCEDURE

Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.

Conventional IM vaccination

Blood would be drawn from those who received a conventional intramuscular rabies booster vaccination in the previous trial.

Group Type ACTIVE_COMPARATOR

Blood drawn after rabies booster vaccination

Intervention Type PROCEDURE

Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood drawn after rabies booster vaccination

Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy HIV-infected adults
* Previously received rabies booster vaccination by participation in the previous clinical trials of the investigators.

Exclusion Criteria

* Have any active opportunistic infections
* Received blood or blood product within 3 months
* Received anti-malarial drugs
* Received rabies vaccination in a previous year.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No